Related Experiment Videos
Oligodendroglioma: CD44 as a possible prognostic opportunity
A M Buccoliero1, A Caldarella, L Arganini
1Dipartimento di Patologia Umana e Oncologia, Università degli Studi di Firenze, Italy.
Clinical Neuropathology
|August 12, 2003
Summary
Standard CD44 glycoprotein expression in oligodendrogliomas may predict tumor recurrence. CD44 standard (CD44H) positivity was linked to higher-grade tumors and increased relapse rates, suggesting prognostic value.
Area of Science:
- Neuro-oncology
- Cancer biology
- Immunohistochemistry
Background:
- CD44 is a cell surface glycoprotein involved in cell adhesion, implicated in tumor growth and metastasis.
- Its standard form (CD44H) and isoforms are expressed across various non-neoplastic and neoplastic cells.
Purpose of the Study:
- To investigate the prognostic role of CD44 standard (CD44H) expression in oligodendrogliomas.
- To correlate CD44H expression with tumor grade and relapse occurrence.
Main Methods:
- Immunohistochemical analysis of CD44 standard expression in 30 oligodendroglioma samples (19 primary, 11 recurrent).
- Correlation of CD44H positivity with Smith tumor grade and patient relapse status.
Main Results:
- CD44H expression was observed in 63% of primary and 73% of recurrent oligodendrogliomas.
- Higher CD44H positivity rates were found in higher-grade (Smith C-D) and relapsed primary tumors (p = 0.020).
- Median survival was similar for CD44H-positive (84 months) and CD44H-negative (91 months) lesions, but relapse association was significant.
Conclusions:
- CD44H expression may serve as a prognostic marker for predicting relapse in oligodendrogliomas.
- Further research is warranted to fully elucidate the role of CD44H in oligodendroglioma progression.